Fibrocor, the Core of Fibrosis Therapeutics.

Developing novel medicines to combat diseases of fibrosis.

Nearly 45% of all deaths in the industrialized world are attributable to diseases of fibrosis.  They include not only the pulmonary fibroses (IPF, ILD) but also liver cirrhosis, most forms of chronic kidney disease, and scleroderma.

Henderson, Rieder and Wynn. Fibrosis: from mechanisms to Medicines. Nature 2020, 587, pages 555–566

Fibrocor’s approach to drug discovery program centres on patient-derived tissue samples to identify and drug critical pathways in the fibrogenic process.
Our patient-derived target discovery platform leverages one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue, enabling the identification of novel disease targets and the development of a robust pipeline of first-in-class therapeutics.

In diseases of fibrosis, excessive scar tissue formation disrupts normal organ function leading to impairement and eventually failure. Recognizing the severity, and unmet need, Fibrocor Therapeutics confronts the challenges by combining its patient-derived target discovery platform with world-leading medicinal chemistry capabilities.

Alport Syndrome is an hereditary kidney disease that is characterized by worsening fibrosis
Learn More
Most cases of pulmonary fibrosis have no known cause and, accordingly, are labelled as Idiopathic Pulmonary Fibrosis
Learn More
Beyond the commoner causes of liver cirrhosis such as alcohol and NASH that primarily affect liver cells
Learn More

Poor Late-stage prognosis

Disease Heterogeneity

Limited treatment options

Targeting Fibrosis with Patients at the Core

Patient-Derived Disease driven Insights at the Heart of Innovation:

One of our key differentiators comprises exclusive access to one of the world’s largest fibrosis tissue biobanks containing kidney, liver, and lung biopsies. These biobanks are connected to best-in-class longitudinal medical records, providing Fibrocor with invaluable patient information for research and development. Focused on this comprehensive data, we gained deep insights into the underlying mechanisms of fibrosis to make significant strides in the field. Our exceptional drug candidates have progressed seamlessly into the pre-clinical assessment, paving the way for transformative advancements in fibrosis treatment.

Molecular-Clinical interface

Longitudinal biobank samples correlated with fibrotic pathology, clinical outcome.

Tissue-cell-disease specificity

Single-cell and bulk RNAseq analysis for target discovery

Focus on novel tractable targets

Fibrosis Molecular pathways, genomic association and key biological insights.

Validation of key candidate compounds

Clinically relevant in vitro fibrosis assays and In vivo disease models.

Promising compounds with exceptional results

Best-in-class candidates (FIB991. FIB992 and FIB918) ready to progress to clinical phase.

Unveiling New Frontiers in Fibrosis Care with our Pipeline

We collaborate with proven scientific experts to ensure the highest scientific rigor and expertise for target validation and candidate identification. We harness the collective knowledge and insights of unique ecosystem to identify disease drivers and assess their novelty, relevance, and drugability. Thorough validation of these targets was performed using cell and animal models, ensuring that only the most promising candidates move forward in our drug discovery pipeline.